Welcome to our dedicated page for Trupanion SEC filings (Ticker: TRUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trupanion, Inc. filings document the company’s pet medical insurance business, public-company governance, and capital structure. Form 8-K reports include quarterly and annual operating results, with disclosures on subscription revenue, enrolled pets, net acquisition cost, adjusted EBITDA, operating cash flow, and other measures used to describe the company’s insurance economics.
The filing record also covers material agreements, including credit facilities, secured borrowings, maturity terms, covenants, and limits on corporate actions. Proxy materials document director elections, board composition, executive compensation, equity awards, shareholder voting matters, and related governance disclosures.
TRUPANION, INC. director Howard E. Rubin received equity compensation in the form of restricted stock units. On May 11, 2026, he was granted three separate awards of 562 RSUs each, for a total of 1,686 RSUs, in connection with his service on the boards of wholly-owned subsidiaries.
The RSUs convert into Trupanion common stock on a one-for-one basis. They vest in four equal installments, with one quarter of the total shares vesting on each of August 22, 2026, November 22, 2026, February 22, 2027, and May 22, 2027, provided Rubin continues his service through each vesting date.
TRUPANION, INC. director Darryl Rawlings reported an internal restructuring-related transaction involving indirectly held common stock. On May 6, 2026, Kuyashii Primary Equities LLC, an entity associated with him, received 1,359 shares after an event of default on a secured loan with stock pledged as collateral. Following this collateral delivery, Kuyashii Primary Equities LLC is shown as beneficially owning 1,435,340 shares of Trupanion common stock indirectly held for Rawlings.
Trupanion reported improved results for the first quarter of 2026. Total revenue was $384.0 million, up 12% from the first quarter of 2025, driven by subscription business revenue of $269.5 million, which grew 16%. Net income was $4.9 million, or $0.11 per basic and diluted share, compared to a net loss of $1.5 million, or $(0.03) per share, a year earlier.
Adjusted EBITDA rose to $17.4 million from $12.2 million. Subscription enrolled pets reached 1,105,783 at March 31, 2026, a 5% increase over March 31, 2025, while total enrolled pets across all segments declined 2% to 1,637,665. Operating cash flow was $14.6 million and free cash flow was $13.7 million. The company held $383.7 million in cash and short-term investments at March 31, 2026.
Trupanion returned to profitability in Q1 2026 as growth in core subscription insurance outpaced costs. Revenue rose to $384.0 million from $342.0 million, driven by a 16% increase in subscription segment revenue to $269.5 million and an 11% rise in monthly average revenue per pet.
Net income was $4.9 million, or $0.11 per diluted share, compared with a $1.5 million loss, helped by improved subscription margins and lower interest expense. Cash, cash equivalents and short-term investments totaled $383.7 million, while operating cash flow was $14.6 million and long-term debt stood at $110.0 million under the PNC credit facility.
TRUPANION, INC. Chief Operating Officer John R. Gallagher executed an open-market sale of 431 shares of common stock at $27.47 per share. This transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, meaning the timing was predetermined. Following the sale, Gallagher directly holds 31,526 shares of Trupanion common stock.
TRUP reported insider sales of Common Stock by John Gallagher: 5,283 shares sold on 02/27/2026 for $140,080.33 and 430 shares sold on 03/30/2026 for $10,952.10. The filing lists the securities as restricted stock issued on 05/25/2023 and 08/25/2023.
Trupanion, Inc. announced that director Max Brodén has informed the company he will not stand for re-election at the Annual Stockholders’ Meeting scheduled for June 10, 2026 at 9 a.m. Pacific Time. His decision is for personal reasons and is not due to any disagreement with Trupanion or its Board.
Brodén plans to continue serving as a director until the 2026 Annual Meeting. The company states that his departure does not affect the strategic partnership between Aflac and Trupanion, and that Aflac remains a committed, aligned shareholder. Trupanion also furnished a shareholder letter included in its 2025 Annual Report under Regulation FD, clarifying that this information is furnished rather than filed under securities laws.
Trupanion, Inc. is asking stockholders at its 2026 annual meeting to elect nine directors, ratify Ernst & Young LLP as independent auditor for 2026, and approve 2025 executive compensation on an advisory basis. The in-person meeting is set for June 10, 2026 at 9:00 a.m. PDT in Seattle, with April 14, 2026 as the record date for voting, covering 43,620,472 common shares outstanding. The board currently has a majority of independent directors, a separate Chair and CEO, and formal audit, compensation, and nominating/governance committees. Non-employee director retainers were $150,000 for 2025 and will rise to $165,000 in 2026, with added committee retainers and a mix of cash and RSU-based compensation.
TRUPANION, INC. Chief Operating Officer John R. Gallagher executed an open-market sale of 430 shares of common stock at $25.47 per share on March 30, 2026, under a pre-established Rule 10b5-1 trading plan. He continues to hold 31,957 shares directly after this transaction.